PBSV Pharma-Bio Serv, Inc.
Services-Management Consulting Services · OTC · SEC CIK 1304161 · Fiscal year ends 10/31
Financial factors as of 2026-07-31 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY3.3%
TTM net income YoY398.5%
TTM EPS YoY115.1%
Revenue 3-yr CAGR-19.3%
Net income 3-yr CAGR-45.2%
Margins
Gross margin32.3%
Operating margin-1.6%
Net margin2.7%
FCF margin-4.4%
EBITDA margin-1.0%
Returns
ROE2.2%
ROA2.0%
ROIC (approx.)-1.7%
Asset turnover0.76x
Leverage & solvency
Liabilities / assets8.7%
Debt / equity0.00x
Current ratio11.30x
Interest coverage—
Cash quality & payout
Operating cash flow / net income-1.65x
Accruals ratio5.3%
Payout ratio—
Capex / revenue0.1%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-10-31 | FY20242024-10-31 | FY20232023-10-31 | FY20222022-10-31 | FY20212021-10-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $9.00M | $9.51M | $16.98M | $19.40M | $20.12M |
| Cost of revenue | $6.09M | $6.99M | $11.91M | $14.52M | $14.76M |
| Gross profit | $2.91M | $2.52M | $5.07M | $4.88M | $5.36M |
| SG&A expense | $3.55M | $3.80M | $3.95M | $3.71M | $9.21M |
| Operating income | -$637,662 | -$1.29M | $1.12M | $1.17M | -$3.85M |
| Pretax income | -$94,260 | -$755,448 | $1.69M | $1.19M | -$1.88M |
| Income tax | $6,203 | $22,171 | $377,307 | $181,679 | $213,246 |
| Net income | -$100,463 | -$777,619 | $1.31M | $1.01M | -$2.09M |
| EBITDA | -$577,796 | -$1.26M | $1.17M | $1.23M | -$3.78M |
| EPS (diluted) | -0.00 | -0.03 | 0.06 | — | — |
| Weighted avg. shares (diluted) | 22.96M | 22.97M | 23.00M | 23.03M | 23.16M |
| Balance sheet | |||||
| Cash & equivalents | $3.38M | $6.77M | $10.45M | $14.46M | $17.47M |
| Short-term investments | $7.48M | $5.98M | $4.53M | $0 | — |
| Receivables | $2.36M | $2.51M | $3.94M | $4.98M | $4.61M |
| Current assets | $13.39M | $15.70M | $19.40M | $19.94M | $22.82M |
| PP&E, net | $116,059 | $169,281 | $32,849 | $73,684 | $105,522 |
| Total assets | $13.65M | $16.29M | $19.90M | $20.65M | $23.92M |
| Current liabilities | $1.74M | $1.89M | $2.15M | $2.11M | $2.67M |
| Total liabilities | $1.74M | $2.58M | $3.78M | $4.09M | $5.01M |
| Shareholders' equity | $11.91M | $13.72M | $16.13M | $16.56M | $18.91M |
| Shares outstanding | 22.91M | 22.96M | 22.96M | 22.94M | 23.00M |
| Cash flow statement | |||||
| Operating cash flow | -$214,886 | -$566,701 | $1.89M | $592,457 | $804,842 |
| Capital expenditure | $6,644 | $159,743 | $7,251 | $19,269 | $10,845 |
| Free cash flow | -$221,530 | -$726,444 | $1.88M | $573,188 | $793,997 |
| Investing cash flow | -$1.47M | -$1.36M | -$4.22M | -$19,269 | $1.30M |
| Financing cash flow | -$1.75M | -$1.73M | -$1.76M | -$3.53M | -$1.75M |
| Depreciation & amortization | $59,866 | $23,311 | $48,086 | $51,107 | $72,728 |
| Stock-based compensation | $35,079 | $47,546 | $45,084 | $71,645 | $56,239 |
| Dividends paid | $1.72M | $1.72M | $1.72M | $3.45M | $1.73M |
| Share buybacks | $31,443 | $11,263 | $34,344 | $81,992 | $25,966 |
Free plan shows the latest 5 periods; Pro shows all 16 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.